MedPath

Nitazoxanide

Generic Name
Nitazoxanide
Brand Names
Alinia, Busulfex
Drug Type
Small Molecule
Chemical Formula
C12H9N3O5S
CAS Number
55981-09-4
Unique Ingredient Identifier
SOA12P041N
Background

Nitazoxanide belongs to the class of drugs known as thiazolides. Nitazoxanide (NTZ) is a broad-spectrum anti-infective drug that markedly modulates the survival, growth, and proliferation of a range of extracellular and intracellular protozoa, helminths, anaerobic and microaerophilic bacteria, in addition to viruses. This drug is effective in the treatment of gastrointestinal infections including Cryptosporidium parvum or Giardia lamblia in healthy subjects. It is generally well tolerated. Nitazoxanide is a first-line, standard treatment for illness caused by C. parvum or G. lamblia infection in healthy (not immunosuppressed) adults and children and may also be considered in the treatment of illnesses caused by other protozoa or helminths . Recently, this drug has been studied as a broad-spectrum antiviral agent due to its ability to inhibit the replication of several RNA and DNA viruses .

Indication

用于治疗隐孢子虫、贾第鞭毛虫、阿米巴原虫引起的原虫性腹泻。

Associated Conditions
Diarrhea caused by Cryptosporidium parvum, Diarrhea caused by Giardia lamblia
Clinical Trials
Related News

Trial to Evaluate Nitazoxanide for Treatment of Mild COVID-19 in Subjects Not at High Risk of Severe Illness

Phase 3
Not yet recruiting
Conditions
COVID-19
Interventions
Drug: Placebo
Dietary Supplement: Vitamin Super-B Complex
First Posted Date
2021-12-14
Last Posted Date
2023-09-29
Lead Sponsor
Romark Laboratories L.C.
Target Recruit Count
600
Registration Number
NCT05157269

Nitazoxanide Pharmacokinetic Parameters in Hepatic Impaired Patients

Phase 1
Completed
Conditions
Moderate Hepatic Impairment
Severe Hepatic Impairment
Liver Diseases
Interventions
First Posted Date
2021-11-11
Last Posted Date
2022-10-14
Lead Sponsor
Genfit
Target Recruit Count
25
Registration Number
NCT05116826
Locations
🇺🇸

Panax Clinical Research, Miami Lakes, Florida, United States

🇺🇸

Orlando Clinical Research Center, Orlando, Florida, United States

Finding Treatments for COVID-19: A Trial of Antiviral Pharmacodynamics in Early Symptomatic COVID-19 (PLATCOV)

Phase 2
Recruiting
Conditions
COVID-19
Interventions
Drug: Nirmatrelvir/ritonavir (e.g. PAXLOVID™)
Drug: Molnupiravir and nirmatrelvir/ritonavir (e.g. PAXLOVID™)
Other: No treatment
Drug: Monoclonal antibodies
Drug: Molnupiravir
First Posted Date
2021-09-13
Last Posted Date
2024-10-28
Lead Sponsor
University of Oxford
Target Recruit Count
3800
Registration Number
NCT05041907
Locations
🇳🇵

Sukraraj Tropical & Infectious Disease Hospital, Kathmandu, Nepal

🇧🇷

Universidade Federal de Minas Gerais, Minas Gerais, Brazil

🇱🇦

Laos-Oxford-Mahosot Wellcome Trust Research Unit, Vientiane, Lao People's Democratic Republic

and more 4 locations

Early Treatment of Vulnerable Individuals With Non-Severe SARS-CoV-2 Infection

Phase 2
Conditions
Covid19
Covid19 Drug Treatment
SARS-CoV2 Infection
Severe Acute Respiratory Syndrome Coronavirus 2
Interventions
First Posted Date
2021-06-10
Last Posted Date
2023-01-31
Lead Sponsor
ANRS, Emerging Infectious Diseases
Target Recruit Count
600
Registration Number
NCT04920838
Locations
🇬🇳

Centre de traitement des maladies à tendance épidémique de Gbessia, Conakry, Guinea

🇧🇫

Centre Muraz/INSP, Bobo-Dioulasso, Burkina Faso

Favipiravir +/- Nitazoxanide: Early Antivirals Combination Therapy in COVID-19

Phase 2
Completed
Conditions
Covid19
Interventions
Other: Nitazoxanide Placebo
First Posted Date
2021-06-09
Last Posted Date
2023-03-24
Lead Sponsor
Coordinación de Investigación en Salud, Mexico
Target Recruit Count
120
Registration Number
NCT04918927
Locations
🇲🇽

Hospital de Infectología "Daniel Méndez Hernández" del Centro Médico Nacional La Raza, Ciudad de Mexico, Azcapotzalco, Mexico

Efficacy and Safety of Nitazoxanide for Post Exposure Prophylaxis of COVID-19 in Household Contacts

Phase 4
Conditions
SARS-CoV-2 Infection
Covid19
Households Contacts
Interventions
Drug: Placebo
First Posted Date
2021-03-09
Last Posted Date
2021-07-02
Lead Sponsor
Fundación Huésped
Target Recruit Count
456
Registration Number
NCT04788407
Locations
🇦🇷

Fundación Huésped., Buenos Aires, Ciudad Autonoma De Buenos Aires, Argentina

Nitazoxanide as a New Local Adjunctive to Nonsurgical Treatment of Moderate Periodontitis

Phase 2
Completed
Conditions
Periodontitis
Interventions
Procedure: Scaling and Root Planing
First Posted Date
2021-02-24
Last Posted Date
2021-02-24
Lead Sponsor
Maha Talaab
Target Recruit Count
40
Registration Number
NCT04768530
Locations
🇪🇬

Faculty of Dentistry, Alexandria University, Alexandria, Egypt

Nitazoxanide in Prevention of Secondary Spontaneous Peritonitis

Phase 3
Conditions
Spontaneous Bacterial Peritonitis
Interventions
First Posted Date
2021-02-10
Last Posted Date
2021-02-10
Lead Sponsor
Tanta University
Target Recruit Count
60
Registration Number
NCT04746937

AGILE (Early Phase Platform Trial for COVID-19)

Phase 1
Active, not recruiting
Conditions
Covid19
Interventions
Drug: Molnupiravir
Drug: NHS standard of care as per COVID-19 treatment guidelines
Drug: Paxlovid
First Posted Date
2021-02-09
Last Posted Date
2024-11-19
Lead Sponsor
University of Liverpool
Target Recruit Count
600
Registration Number
NCT04746183
Locations
🇬🇧

Manchester University NHS Foundation Trust, Manchester, United Kingdom

🇿🇦

Desmond Tutu Health Foundation, Cape Town, South Africa

🇿🇦

Ezintsha, Johannesburg, South Africa

and more 3 locations

EAT-DUTA AndroCoV Trial

Phase 2
Completed
Conditions
Covid19
Interventions
Drug: Placebo
First Posted Date
2021-01-28
Last Posted Date
2021-01-28
Lead Sponsor
Corpometria Institute
Target Recruit Count
138
Registration Number
NCT04729491
Locations
🇧🇷

Corpometria Institute, Brasília, DF, Brazil

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy